Background: Host genetic factors that may confer a susceptibility to chronic hepatitis and the progression of hepatocellular carcinoma (HCC) are largely unknown. Apoptosis is an important fail-safe check for the hepatitis virus and HCC development, in which Fas/FasL hepatocyte expression contributes substantially. Aim: To determine whether the Fas/FasL gene promoter polymorphism at Fas-670, Fas-1377 and Fas-L844 are associated with the risk of virus hepatitis or the prognosis of HCC patients. Patients and methods: We conducted a retrospective hospital-based caseecontrol study in which 142 HCC patients were enrolled. The study patients were divided into three groups: 1) hepatitis B with Lamivudine treatment (N ¼ 107), 2) hepatitis C with interferon treatment (N ¼ 50), and 3) a non-HCC control group of patients (N ¼ 300). Of the 142 total enrolled patients from the first two groups, 110 underwent liver resection. There were 59 patients with early recurrence (<1 year post operation), 31 patients with late stage HCC (CLIP score 2e6), and 22 patients with AFP >400 ng/ml. All of the patients in these groups were tested for Fas/FasL polymorphism by PCR-RFLP. The frequency of allele and genotype were compared between each group. The significant SNP (single nucleotide polymorphism) correlated with patient clinical characteristics and was a surrogate for recurrence or survival analysis.
Introduction
Epidemiological studies have shown that viral infections such as hepatitis C virus (HCV) and hepatitis B virus (HBV) are important factors contributing to hepatocellular carcinoma (HCC) development. Chronic HCV leads to cirrhosis in approximately 20% of patients over a 10e20 year period, and approximately 10e20% of cirrhotic patients will develop HCC within 5 years.
1,2 Viral hepatitis is a major etiological agent of chronic hepatitis, cirrhosis and hepatocellular carcinoma. Fas-mediated apoptosis is the major cause of hepatocyte damage during liver disease. 3 Although molecular events of HCC carcinogenesis have been studied extensively, the mechanism remains largely elusive. In patients with HBV infection, the HBx gene encodes a protein called HBV X protein 1 and its interaction with proteasome subunits might be responsible for HCC carcinogenesis. 2 In patients infected with HCV, the mechanisms causing viral evasion of cell-mediated immune responses leading to apoptotic death of hepatocytes might contribute to viral persistence. Such a mechanism might also contribute to the development of liver cancer. 4 Progressive liver damage from viral hepatitis may be the results of repeated attempts by cytotoxic T lymphocytes (CTL) to clear infected hepatocytes. 5 Histological necroinflammation is a well-recognized phenomenon in chronic HCV infection. Reports have shown that altered regulation of apoptosis was associated with the pathogenesis of HCC and dysplasia, 6 primary biliary cirrhosis, 7 viral hepatitis 1e4 and liver disease induced by ethanol, 8 bile salts, 9 toxins and drugs. 10 Indeed, both HBxAg and the HCV core protein have been reported to induce the expression of FasL on HCC cells, which counter-attack CTL for immune evasion.
11,12
Fas/FasL, a transmembrane receptor, is a member of the tumor necrosis factor receptor superfamily, which play an important role in embryogenesis, autoimmunity, liver cirrhosis and tumorigenesis. 3, 4 Engagement of the Fas ligand (FasL) triggers programmed cell death, which is important in apoptosis mediated by cytotoxic T lymphocytes (CTL) and natural killer (NK) cells. 13 Genetic polymorphisms with functional differences of Fas/FasL genes were recently reported to be associated with autoimmune diseases including cervix cancer, 14 HCV related liver cirrhosis, 15, 16 lung cancer, 17 and esophageal cancer. 18 The present study was intended to test the hypothesis that genetic polymorphisms of Fas/ FasL promoter may be associated with individual susceptibility to virus hepatitis, and the prognosis of HCC in a Taiwanese population.
Materials and methods

Patients
A retrospective hospital-based caseecontrol study was conducted. The study cases included 157 liver cirrhosis patients without HCC undergoing antivirus treatment, and 142 HCC patients, all of which were diagnosed and treated at the Tri-Service General Hospital, Taipei, Taiwan, between 1999 and 2003. The latest follow-up for these patients was June 1st, 2013. The antivirus treatment protocol was according to the guidelines of the Bureau of National Health Insurance in Taiwan. All patients were assessed for general characteristics, laboratory data, treatment modalities, and prognosis. There were 142 patients with HCC recruited out of which 100 and 35 patients were found to be positive for HBV and HCV infection, respectively. From the 142 patients with HCC, 110 underwent liver resection. All of the surgical HCC patients were assessed for clinical characteristics, laboratory data, liver function status, pathology report, tumor size and pattern, viral hepatitis status, CLIP stage, 19 Child-Pugh score, recurrence time, and survival follow-up. In the cirrhotic patients, 107 patients were HBsAg serum positive with symptoms with lamivudine treatment and 50 patients were anti-HCV antibody positive with symptoms with interferon therapy. Patients that were infected with both HBV and HCV were excluded from the cirrhotic group. Age matched (N ¼ 300) controls were enrolled, where volunteers attending their routine physical check-up agreed to participate and provided informed consents. Exclusion criteria included any history of immune-compromised conditions or chronic or acute viral infections and other cancers. All the patients were investigated and managed under the standard protocol at the same hospital. The study was approved by the Institute Review Board of Ethics of the Tri-Service General Hospital.
Determination of Fas/FasL promoter polymorphisms
Whole blood from patients and controls were extracted for DNA by using QIAGEN DNA extraction kits (QIAGEN, Dusseldorf, Germany) following the manufacturer's protocol. The genomic DNA concentration was determined by using fluorescent illumination with PicoGreen dye (Molecular Probes, OR). Polymorphisms were determined using TaqMan probes as previously described. . The genotypes were determined by the endpoint products. The polymorphic sequences of ten randomly selected samples were determined for each SNP by using DNA sequencing (CEQ8000, Beckman Coulter, Fullerton, CA, USA).
Statistical analysis
The difference in mean ages between the HCC cases and controls were examined using Student's t-test. Associations of Fas/FasL genotype and allele frequencies with control, HCC and virus-related hepatitis were analyzed by use of the c2 test and Fisher's exact test as necessary. Survival probabilities were calculated using the KaplaneMeier method and compared using the log-rank test. Cox proportional hazard function model was used to test the independent prediction of prognosis. For all statistical tests, the level of significance was set at 0.05.
Result
The gender distributions (M/F) in the cirrhosis group and the HCC group were 106/51 and 100/42, respectively. Overall, there was no real difference between these distributions and the control group (200/100). The clinical characteristics were summarized in Table 1 . The mean patient age in the cirrhotic group was 59.3 ± 13.4 years, and in the HCC group was 58.9 ± 13.3 years; similarly, there was no difference from the control group's mean patient age. There were 107 patients of the cirrhotic group that had a history of HBV infection, and 50 patients with a history of HCV infection. In the HCC group, there were 100 patients with HBV infection and 35 patients with HCV infection, again showing little difference in distribution between the two groups. One of the exclusion criteria for the control group was hepatitis virus infection, so all patients in the control group had no history of hepatitis virus infection.
The association of Fas-FasL genotype between patients with and without liver diseases
In HCC group, there were 86 patients with AFP <400 ng/ml, 22 patients with AFP !400 ng/ml, 79 patients with early stage of HCC (CLIP score 0e1), and 31 patients with late stage HCC (CLIP score 2e6).
The association between patients with HCC or cirrhosis of the liver and controls was assessed in Table 2 . In patients with HCC, the AA, AG and GG genotype distribution of Fas670 was 26.1, 51.4 and 22.5, respectively, which showed no significant difference from the controls (30.3, 50.0 and 19.7). The AA, AG and GG genotype distribution of Fas670 in patients with cirrhosis of liver was 23.5, 54.0 and 22.5, respectively, which again was no different than those in the control group. Similarly, we could not identify any significant difference between patients with HCC or cirrhosis of the liver and controls in Fas1377 and FasL844.
The association between viral status and Fas-FasL genotypes in patients with HCC or cirrhosis
In patients with HCC and HBV infection, the genotype distribution of AA, AG and GG in Fas670 is 25.5, 54.3 and 20.2, respectively, which was no different to those in patients with HCC and HCV infection (25.7,54.3 and 22.9) ( Table 3 ). There were not any differences between patients with HBV and HCV infection in Fas1377 and FasL844.
In patients with cirrhosis and HBV infection, the GG genotype of Fas1377 was 28.7%, which was significantly higher than those in patients with HCV infection (16.0%, P ¼ 0.04). When compared with the controls, patients with cirrhosis and HCV infection showed significantly lower AA genotype of Fas670 (16. 
Genetic polymorphisms and CLIP stage in HCC
The association between CLIP stages and genotypes was assessed in Table 4 . The frequencies of CC, TC and TT genotype of FasL844 in early stage (CLIP 0e1) was 57.0,36.7 and 6.3, respectively, which was significantly different from those in patients with late stage HCC (CLIP 2e6) (35.5, 45.1 and 19.4, respectively, p ¼ 0.0002). The genotype comparison of Fas670 and Fas1377 in patients with HCC early and late stage also revealed no differences (data not shown). When stratified by the parameters of CLIP stage system, however, the association between FasL844 genotype and AFP level was significant. The TT genotype frequency of FasL844 in patients with higher AFP level (!400 ng/dL) was significantly higher than those with lower AFP level (<400 ng/dL) (p ¼ 0.0043). No other differences could be identified in the other three parameters of the CLIP scoring system (data not shown).
The associations between SNPs and prognosis
In the HCC group, there were 59 patients with early recurrence (<1 year post operation), and 51 with late recurrence (>1 year post operation) (data not shown). There were no significant differences between early and late recurrence groups in the distribution of AA, AG and GG genotypes of Fas670, Fas1377 and the distribution of CC, TC, and TT of FasL844 (data not shown). The overall 10-year survival rate between FasL genotype C/C and T/C þ T/T also demonstrated no difference. (p ¼ 0.35) (Fig. 1 ).
Discussion
Our results showed an association between the Fas genotype and HCV-associated cirrhosis of the liver. The FasL genotype was also associated with CLIP stages of HCC, where AFP is detrimental associated with polymorphism and the risk of severe cirrhosis with chronic HCV infection. The major SNPs in the Fas promoter region were not associated with HCC patients. When factoring in the clinical parameters of the CLIP staging system, Child classification, tumor numbers, AFP levels and portal invasion for HCC patients, only patients with AFP level !400 ng/dL had an association with FasL À844 T/C polymorphyism.
HCV does not kill the cells it infects, but triggers an immunemediated inflammatory response (hepatitis) that either rapidly clears the infection or slowly destroys the liver, causing the development of HCC and cirrhosis. The outcome is largely determined by the efficiency of the antiviral immune response. So the innate immune response might be expected to influence the outcome of infection. 4, 20 Apoptosis is an active, genetically programmed phenomenon of cell death characterized by a unique sequence of events, with morphological features distinct from necrosis. 21 Three pathomorphologic features are suggestive of increased apoptosis in the liver of patients with chronic hepatitis C: (1) the presence of shrinkage and fragmentation of nucleus/cytoplasm in areas of piecemeal necrosis; (2) the presence of acidophilic bodies; and (3) focal cell drop out in the liver lobule. Increased expression of Fas, one of the most important members of the tumor necrosis factor family receptors and able to act as a transducer for the apoptotic signal to complete programmed cell death, has been described in chronic hepatitis C. Hepatic up-regulation of Fas was found to correlate with more severe inflammation and ongoing HCV infection. 3, 22, 23 Fas expressing cells are potential targets of cytotoxic T lymphocytes bearing Fas ligand. The interaction between Fas ligand and its receptor, Fas, induces apoptosis in the target cell. Hepatocyte expression of Fas has been shown to be common in chronic HCV infection suggesting that apoptosis is a frequent occurrence in this disease. 24 Active inflammation was observed in chronic hepatitis C patients who had high levels of serum sFas, suggesting that sFas may serve as a serological indicator of active inflammation in chronic hepatitis C. 22, 25 Serum sFas levels may be correlated with the degree of inflammation in the liver and Fas expression on hepatocytes. Because apoptosis of hepatocytes is determined not only by Fas/sFas expression but also by expression of FasL/soluble form of FasL, the inducing effect of FasL on CTL might have exceeded the inhibitory effect of sFas. 3, 22, 25 Nevertheless, correlation between Fas genotype and histopathological activity grade is consistent with a body of data indicating that Fas-mediated hepatocyte apoptosis contributes significantly to the pathology of chronic hepatitis C. In particular, activity grade in hepatitis C patients has been correlated with both the level of Fas expression and the extent of apoptosis in The numbers shown in this table indicate the population percentages. The numbers in the parentheses in the first column denote the case number. ns: no significant difference; Liver Dz: liver disease; HCC: hepatocellular carcinoma. hepatocytes. Genetic polymorphyisms that change the level of Fas expression in hepatocytes could therefore alter hepatocyte apoptosis, and hence affect the activity grade of HCV patients. 26 Genetic polymorphyism in the Fas gene may account for some of the histopathological variability in chronic hepatitis. Hepatitis C is a viral infection with a highly variable disease course; approximately 20% of infections are resolved spontaneously, and progressive fibrosis eventually leads to cirrhosis in 20e30% of chronically infected patients. In contrast, the role of cytokine gene polymorphyisms in HCV infection is less clear. Of some importance is that the correlation between Fas -1377G, À690C, À670A haplotype and lower activity grade was stronger in McIlroy's study. 2, 26 These results were similar to our results in that the genotypes of Fas-1377 G/G and Fas-670 A/A have the lower risk for HCV infected cirrhosis. The data suggests that the SNPs in the Fas promoter regions strongly correlate to the severity of cirrhosis caused by HCV infection. The Fas/FasL system plays an important role in tumor outgrowth and metastasis. 3,5,14,22e27 FasL expressed in colorectal carcinoma cells may kill the Fas-positive immune effect of TILs and had a poor prognosis. 12 The expression of FasL on HCC tumor cells is thought to be a mechanism that tumors employ to escape immune surveillance 22, 28 and may induce apoptosis of activated T lymphocytes and had a worse prognosis. 27 The SNPs of FasL have not been well-studied regarding cancer progression, nor have issues of survival and disease-free survival been addressed. In our study, the genotype of FasL844 C/C had a higher rate in the early CLIP score cancer stage and a lower AFP level. It means that the genotype of FasL844 C/C is related to the progression of HCC. Then, we analyzed the overall survival rate. Although there was no significant difference between patients with genotype FasL844 C/C and that of T/C þ T/T, but tended to have longer survival time. We could not determine these patients' survival rates or DFS by using SNP, but they may play an important role in this study and require additional review and comprehension. The status of Fas and Fas ligand expression can predict recurrence of hepatocellular carcinoma. These results suggest that the evaluation of Fas and Fas ligand expression potentially has a significant prognostic value for DFS of HCC patients, in addition to patient clinical stage, and can be regarded as a new prognostic marker. 25 Our results suggest that for SNPs of Fas/FasL, there were no significant differences in tumor recurrence within 1 year. The clinical treatment may confound the disease's natural process and cause difficulties of statistical significance.
In conclusion, the SNPs of Fas/FasL promoters are not correlated with long-time survival in HCV virus-related HCC. Fas polymorphyisms are related to HCV related cirrhosis. FasL polymorphyisms are related to the progression of HCC and may correlate to the serum AFP level in patients with HCC. In future studies, we need to assemble a greater number of cases and attempt to identify the relationship between FasL polymorphyisms and tumor tissue FasL expression.
